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Abstract
Background: The cyclobenzaprine structure is similar to amitriptyline; however, tricyclic antidepressant
(TCA)-like wide complex dysrhythmia has not been reported. Our objective was to determine the
incidence of TCA-like effects in cyclobenzaprine overdoses as reported to 6 poison centers for 2 years.
We compared the incidence of these effects to amitriptyline overdoses collected during the same period.
Methods: We performed a retrospective review of 2 years of cases as reported to the Texas Poison
Center Network. We identified sole ingestions of cyclobenzaprine and of amitriptyline. Cases had a
recorded clinical outcome and clinical effect. A trained reviewer used a standard data collection sheet
within a secured electronic database. One investigator audited a random sample of charts.
Results: We identified 3974 cases of cyclobenzaprine calls. Of these, we collected 209 cases of acute
overdoses without coingestions. There were no deaths. No cases of cyclobenzaprine ingestions were
reported to have died or have a wide QRS or ventricular dysrhythmia. Seizures were reported in 2 cases;
however, both were unrelated to cyclobenzaprine. Hypotension was reported in 1.4% (3/209) of cases,
and a vasopressor was used in one case (0.5%). Patients with an amitriptyline overdose were more likely
to have seizure, coma, tachycardia, a wide QRS or ventricular dysrhythmia, and have received sodium
bicarbonate or be intubated.
Conclusions: Cyclobenzaprine overdoses were not reported to cause widened QRS, ventricular
dysrhythmias, or seizures, and hypotension was rarely reported. Tricyclic antidepressant-related effects
occurred more often in our comparison group of amitriptyline overdoses.
© 2011 Published by Elsevier Inc.
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1. Introduction
Cyclobenzaprine is tricyclic amine, structurally similar to
amitriptyline, which is used for muscle pain and spasm [1]
(Fig. 1). It has antihistaminic, anticholinergic, and sedative
properties. It is a weak inhibitor of norepinephrine and
serotonin reuptake. It was created as antidepressant but had
more adverse effects and less antidepressant effects than
other tricyclic antidepressants (TCAs) [2,3]. It is the most
common prescribed muscle relaxant and accounts for 18% of
all prescriptions written for chronic back pain [4]. However,
effectiveness for chronic pain is inconclusive [5,6]. It
accounts for 8760 overdoses a year, 30% of all overdoses
from muscle relaxants [7].
Because of its similar structure to amitriptyline and other
tricyclics (a difference of one double bond), previous
publications and authors suggest wide QRS and ventricular
dysrhythmias are possible adverse effects of cyclobenzaprine
overdose [8,9]. Although in one series of unintentional and
intentional ingestions, no wide complex dysrhythmia
occurred, a recent abstract showed a slightly widened QRS
hours after ingestion [10,11].
We sought to determine the incidence of ventricular
dysrhythmias and a widened QRS in a large series of
cyclobenzaprine overdoses as reported to 6 poison centers
for 2 years. We also sought to determine the incidence of
other serious TCA-like effects. Finally, we aimed to compare
the serious adverse effects of cyclobenzaprine to amitripty-
line over the same period.
2. Methods
2.1. Study design
2.1.1. Setting and selection of participants
We performed a retrospective cohort study approved by
our institutional review board. We searched 2 years (2005-
2006) of the electronic database Toxicall of the Texas Poison
Center Network. This database includes all calls made to a
poison center within Texas. We used the POISONDEX
product identification codes for cyclobenzaprine and ami-
triptyline to identify all cases. Our network is made of 6
poison centers, and calls are received and documented by
trained poison information specialists (SPIs). They enter
clinical notes and document standardized codes for common
symptoms, signs, treatments, procedures, and disposition.
They also enter free text clinical notes. We included all acute
intentional ingestions of cyclobenzaprine without coinges-
tions. Cases had a recorded clinical outcome and clinical
effect. Patients 12 years and older were included. We used
the same criteria to search for all amitriptyline ingestions.
Symptoms, signs, treatments, procedures, and outcomes
were extracted from the database through chart review of the
clinical notes and coded diagnoses and treatments. We did
not use the outcomes of “No effect,” “Minor,” “Moderate,”
“Major,” and “Death” as defined according to the American
Association of Poison Centers outcome criteria [7]. Instead,
we recorded the effects and outcomes as documented by the
specialist in poison information or toxicologist.
2.1.2. Data collection and processing
We saved the charts electronically and then printed and
reviewed them individually. One trained abstractor (JM)
reviewed the charts and entered the data into a secure
spreadsheet. The abstractor reviewed the clinical notes for
symptoms, signs, and treatments not coded by the SPI. One
of the investigators (VB) trained the abstractor. The
abstractor trained on 50 charts not included in the study
cohort. He was given feedback on data abstraction and
corrected mistakes. The standard data collection tool was
devised before this run-in period and revised before the chart
review began.
We used the American Association of Poison Centers
definitions for dysrhythmia (ventricular tachycardia, ventric-
ular fibrillation, or torsades de pointe), hypotension (systolic
blood pressure, b90 mm Hg), tachycardia (pulse rate, N100
mm Hg), and hypertension (diastolic blood pressure, N90Fig. 1 Structures of cyclobenzaprine and amitriptyline.
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mm Hg) [12]. We defined a wide QRS as more than 100
milliseconds [13]. For a discrepant case, 2 authors reviewed
the case and determined if the outcome was present to ensure
the broadest capture of cases. Other data collection variables
included demographics (age, sex), exposure reason, symp-
toms, treatments, procedures, and disposition. Both coded
and free text answers were included. Definitions and
outcomes were defined before abstraction. Once the chart
review began, periodic meetings were completed to resolve
discrepancies. One investigator (VB) audited a random
sample of 10% the charts to assess for accuracy. He reviewed
the outcomes for wide QRS, ventricular dysrhythmia,
seizure, tachycardia, and hypotension. The auditor was
blinded to the disposition and ingestant for each case, and he
was blinded to the initial abstractor's data.
2.1.3. Outcomes measured
Our primary outcome was ventricular dysrhythmia or
widened QRS on the electrocardiogram. This outcome was
included if noted in the coded “clinical effects” categories or
clinical notes section of the database collection form. Our
secondary outcomes were hypotension, seizure, tachycardia,
use of sodium bicarbonate for wide QRS, intubation,
intensive care unit (ICU) admission, death, or use of
defibrillation, antidysrhythmics, vasopressor agents, antiepi-
leptic medications, or sodium bicarbonate for wide QRS.
Clinical effects due to the ingestant were included.
Discrepancies were resolved by consensus of 2 authors.
We compared the signs, treatments, procedures, and out-
comes with the group of amitriptyline ingestions. We chose
amitriptyline because of its effects as a potent tricyclic and its
similarity in structure to cyclobenzaprine [1].
2.1.4. Primary data analysis
We entered all data into a password-protected
electronic spreadsheet (Microsoft Excel, 2007; Microsoft
Corporation, Redmond, Wash). We performed descriptive
statistics. We compared with groups with χ2 or Fisher
exact (when indicated) for selected clinical features,
treatments, and outcomes between cyclobenzaprine and
amitriptyline.
3. Results
We identified 3974 cases of cyclobenzaprine calls to the 6
poison centers in 2005 and 2006. Of these, 1043 were human
exposures. Of these, we collected 209 cases of cyclobenzapr-
ine acute intentional ingestions without coingestions. Thirty
percent were male (63/209), and the mean age was 30.3 years
(range, 12-63 years old) (Table 1). There were no deaths in
the cyclobenzaprine group. No case of cyclobenzaprine
ingestions was reported to have a wide QRS or ventricular
dysrhythmia (Table 2). Two patients received sodium
bicarbonate, but no explanation was given and no case had
dysrhythmia, seizure, or hypotension noted. Seizures were
reported in 2 cases; however, one had hyponatremia and the
other had a large brain mass. In both cases, the SPI
documented that the seizures were unrelated to cycloben-
zaprine. Our abstractor concurred with these assessments.
Drowsiness was reported in 42% of cases, and intubation was
reported in 5% of cases. Hypotension was reported in 1.4%
(3/209) of cases, and a vasopressor (dopamine) was used on
one of these cases (0.5%). In the case with dopamine use, a
Table 1 Demographics of patients with acute intentional
cyclobenzaprine and amitriptyline ingestions compared with
χ2
Category Cyclobenzaprine (%),
(n = 209)
Amitriptyline (%),
(n = 262)
P
Male 63 (30) 94 (36) .2
Mean
age (y)
30.4 35.5 –
Decontamination
Gastric
lavage
14 (0.07) 18 (0.18) 1.0
Activated
charcoal
92 (44) 141(54) .041 a
Disposition
Admitted 87 (42) 170 (65) .001 a
Admitted
to ICU
40 (19) 132 (50) .001 a
a Statistical difference.
Table 2 Comparison of clinical outcomes and treatments
between cyclobenzaprine and amitriptyline acute intentional
ingestions with χ2
Category Cyclobenzaprine
(%), (n = 209)
Amitriptyline
(%), (n = 262)
P
Serious clinical effects
Seizure 0 (0) 6 (0.02) .036 a
Hypotension 3 10 (0.04) .16
Wide QRS or
ventricular
dysrhythmia
0 (0) 30 (11) .0001 a
Coma 1 (0.004) 29 (11) .0001 a
Death 0 (0) 1 (0.004) .44
Other clinical effects
Hypertension 30 (14) 53 (20) .11
Drowsiness 87 (42) 127 (48) .16
Tachycardia 57 (27) 112 (43) .0005 a
Treatments
Sodium
bicarbonate
3 (0.01) 82 (31) .0001 a
Vasopressor 1 (0.004) 5 (0.02) .093
Intubation 10 (5) 56 (21) .0001 a
Antiseizure
medication
0 (0) 2 (0.008) .51
Cardioversion or
defibrillation
0 (0) 1 (0.004) .44
a Statistically significant.
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urine toxicology screen was positive for barbiturates. No
case of rhabdomyolysis was reported.
We compared the clinical features, treatments, proce-
dures, and dispositions of patients with cyclobenzaprine
overdose to those with amitriptyline overdose during the
same period (Table 2). Patients with an amitriptyline
overdose were more likely to have seizure, coma,
tachycardia, a wide QRS, or ventricular dysrhythmia and
have received sodium bicarbonate. They were also more
likely to be admitted to the ICU and be intubated. The
proportion of patients in the amitriptyline group with
hypotension or vasopressor use was greater, but there was
no statistical difference between groups. No patient in either
group received physostigmine or antidysrhythmics. Two
patients received nonbenzodiazepine antiseizure medica-
tions in the amitriptyline group and none in cyclobenzaprine
group. Reversal agent use (naloxone or flumazenil) was
similar in both groups.
Audit of 10% of the charts by a reviewer showed overall
agreement for wide QRS or ventricular dysrhythmia with a
κ of 1.0 (95% confidence interval [CI], 1.0-1.0). Agreement
for were seizures (κ, 1.0), tachycardia (κ, 0.77; 95% CI,
0.34-1.2), and hypotension (κ, 0.83; 95% CI, 0.5-1.2) were
also high. There were no deaths in the sample.
4. Discussion
The results of our study suggests that widened QRS and
ventricular dysrhythmias are rare after acute intentional
cyclobenzaprine overdose based on cases reported to our 6
poison centers over 2 years. Our patients manifested
anticholinergic symptoms (sedation, tachycardia, mild
hypertension) but did not develop the serious complications
of TCA effects such as dysrhythmia and seizure, despite its
structure is similar to TCAs. Hypotension was uncommon
(3 cases). In addition, significant tricyclic effects were more
common in the amitriptyline group. As a surrogate marker of
severity of illness of the patients in the amitriptyline group,
the rates of admission, ICU admission, intubation, and use of
sodium bicarbonate were higher.
Although textbooks and review articles suggest dysrhyth-
mia and other serious TCA-like effects can occur, previous
cases and a large case series do not support this [8,9,14]. In
several cases of cyclobenzaprine overdose, seizure, dys-
rhythmia, and hypotension were not reported [14,15]. In the
series by Dr Spiller [10] of undifferentiated unintentional
and intentional cases of all ages reported to several poison
centers, no patient developed ventricular dysrhythmia or
seizure, and no patient died. These results were similar to
ours. In addition, hypotension occurred in less than 2% of
cases older than 10 years, and vasopressors were used in less
than 1% of cases, which are also similar to our results.
Although the study by Spiller is similar to ours, we only
included acute intentional overdoses in subjects older than
11 years; the group assumed to have the highest risk for
developing toxic effects. In addition, our methods for data
abstraction were explicit and verified by audit as outlined by
Gilbert et al [16]. Finally, we directly compared our risk of
TCA-like effects with a parallel group of acute intentional
amitriptyline overdoses during the same period and poison
centers. Our data are also consistent with postmarketing data
that reported seizures and dysrhythmias each in less than
0.1% of cases [17]. However, in one unpublished case,
authors reported a slightly widened QRS (90 to 100
milliseconds) after ingesting an estimated 2750 mg of
cyclobenzaprine. However, this widening occurred on the
second hospital day, which is not consistent with typical
tricyclic effects that usually occur within the first 6 hours of
ingestion [18]. The patient received sodium bicarbonate
infusion, and the QRS narrowed to 86 milliseconds by
hospital day 12 [11]. Death has been reported after
cyclobenzaprine ingestion; however, both cases had a
respiratory depressant coingestant, and the cyclobenzaprine
dose ingested was calculated from postmortem levels, which
are unreliable [19].
Although the mechanism for the lack of TCA-like effects
is unclear, there are 2 plausible mechanisms. First, although
cyclobenzaprine is structurally similar to amitriptyline
(difference of one double bond), it is possibly less potent
than other tricyclics [3]. In animal models, it also has some
antiepileptic effects ,which is consistent with its possible
antispastic effects [20]. Second, one tablet is 10 mg, thus,
intentional ingestions greater than 1 g are difficult to achieve,
and cardiotoxic and neurotoxic doses are not ingested
[10,15]. However, several cases of 1 to 3 g have been
reported without seizures and dysrhythmia, thus, the lack of
toxicity is likely a combination of mechanisms—a lack of
potency and insufficient dose. Large cyclobenzaprine over-
doses can still induce severe sedation and tachycardia
requiring intensive monitoring and intubation as evidenced
in our study.
This study has several limitations. First, our study used
data from public and health care provider calls to poison
centers [21]. It is possible that patients with severe adverse
effects were not reported to the poison center and managed
with consultants at the hospital. In addition, the primary
provider may not have reported the serious adverse effects to
the poison center specialist. Second, the data are only from
the poison center data, not hospital records, which would be
more detailed. In addition, the follow-up on the cases is
limited, although most of the severe effects would likely
occur in the first 24 hours of admission. Another limitation is
the moderate sample size for 2 years. It is possible that a
larger sample size collected over several more years could
capture patients with dysrhythmias or seizures, if they were
to occur. However, our data suggest the risk of these adverse
effects are less than 0.5% and is consistent with previous
reports [10,17]. Our data were collected from Texas; results
could vary in other geographic regions, although, cycloben-
zaprine use is ubiquitous and our results are consistent with
reports from outside Texas. Finally, the higher rates of
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intubation and ICU admission could be a secondary concern
for potential adverse effects of TCA rather than a surrogate of
illness severity. Nonetheless, the rates of intubated and ICU
admission were lower in the cyclobenzaprine group and is
consistent with the lower rates of severe tricyclic-like effects
in the cyclobenzaprine group in our study.
In conclusion, widened QRS, ventricular dysrhythmias,
seizures, or death was not reported in our study of acute
intentional ingestions of cyclobenzaprine reported to poison
centers. Hypotension rarely occurred, although the differ-
ence between cyclobenzaprine and amitriptyline was not
significant. Rates of these tricyclic effects were much higher
in our parallel comparison group of amitriptyline overdoses.
Cyclobenzaprine overdoses should be observed for sedation
and tachycardia, and cases should be managed for anticho-
linergic toxicity and evaluated for coingestions rather than a
tricyclic-like syndrome.
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